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Abstract An overview of the current pharmacotherapy of
central vestibular syndromes and the most common forms
of central nystagmus as well as cerebellar disorders is
given. 4-aminopyridine (4-AP) is recommended for the
treatment of downbeat nystagmus, a frequent form of
acquired persisting fixation nystagmus, and upbeat nys-
tagmus. Animal studies showed that this non-selective
blocker of voltage-gated potassium channels increases
Purkinje cell excitability and normalizes the irregular firing
rate, so that the inhibitory influence of the cerebellar cortex
on vestibular and deep cerebellar nuclei is restored. The
efficacy of 4-AP in episodic ataxia type 2, which is most
often caused by mutations of the PQ-calcium channel, was
demonstrated in a randomized controlled trial. It was also
shown in an animal model (the tottering mouse) of episodic
ataxia type 2. In a case series, chlorzoxazone, a non-se-
lective activator of small-conductance calcium-activated
potassium channels, was shown to reduce the DBN. The
efficacy of acetyl-DL-leucine as a potential new symp-
tomatic treatment for cerebellar diseases has been
demonstrated in three case series. The ongoing randomized
controlled trials on episodic ataxia type 2 (sustained-
release form of 4-aminopyridine vs. acetazolamide vs.
placebo; EAT2TREAT), vestibular migraine with meto-
prolol (PROVEMIG-trial), cerebellar gait disorders (sus-
tained-release form of 4-aminopyridine vs. placebo;
FACEG) and cerebellar ataxia (acetyl-DL-leucine vs. pla-
cebo; ALCAT) will provide new insights into the phar-
macotherapy of cerebellar and central vestibular disorders.
Keywords Cerebellar ataxia  Central vestibular
disorders  Vestibular migraine  Aminopyridines 
Episodic ataxia type 2  Downbeat nystagmus
Introduction
In this overview, the current pharmacological treatment of
central vestibular vertigo, cerebellar disorders and the most
common forms of central nystagmus are presented. These
disorders are usually associated with vertigo and dizziness,
which are among the most frequent symptoms with which
patients present to primary care physicians with a 30 %
lifetime prevalence [1]. The general prerequisites for suc-
cessful treatment of dizziness and nystagmus are a correct
diagnosis, the correct drug, an appropriate dosage, and a
sufficient duration of the treatment [5]. Vertigo and dizzi-
ness due to central vestibular disorders are often associated
with nystagmus, which causes blurred vision and impaired
visual acuity due to oscillopsia. Depending on the under-
lying etiology, additional cerebellar and brain stem signs
may occur [2]. In recent years, progress has been made in
the symptomatic treatment of cerebellar disorders such as
episodic ataxia type 2 (EA2) as well as downbeat nystag-
mus (DBN), in particular due to the use of aminopyridines
[3, 4].
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Non-randomized and non-placebo-controlled clinical
trials on the treatment of different forms of dizziness and
nystagmus are not state-of-the-art and have considerable
deficits. Thus, there is a strong need for multicenter, pla-
cebo-controlled trials for vestibular and ocular motor dis-
orders. The ongoing trials in the field are also described
(Table 1) and perspectives for future therapeutic interven-
tions are discussed.
Downbeat, upbeat nystagmus and other forms
of nystagmus
DBN is a frequent form of acquired fixation nystagmus [8]
and manifests with oscillopsia, postural instability, and
cerebellar gait disorder [9, 10]. Additional ocular motor
signs such as gaze-evoked nystagmus and deficient smooth
pursuit eye movements are often associated with DBN and
indicate a cerebellar dysfunction [9, 11, 12]. In the majority
of patients, DBN is caused by a bilaterally impaired
function of the cerebellar floccular lobe due to neurode-
generation [8, 13]. Different GABAergic substances have
been used to treat DBN, but with only moderate success
[14]. 3,4-diaminopyridine (3,4-DAP), which is a non-se-
lective blocker of the Kv family of voltage-gated potassium
channels, effectively suppresses DBN probably via an
inhibition of potassium channels of Purkinje cells [15].
4-aminopyridine (4-AP) also alleviates the symptoms of
DBN [16] (Fig. 1), particularly in patients with cerebellar
atrophy [17]. In a double-blind prospective crossover
study, equivalent doses of 4-AP and 3,4-DAP were com-
pared. 4-AP is more lipid-soluble, crosses the blood–brain
barrier more easily, and turned out to be superior to 3,4-
DAP at reducing the slow-phase velocity (SPV) of DBN
[18]. Both aminopyridines were well tolerated and showed
no major side effects apart from nausea, transient pares-
thesia, or headache. In a randomized double-blind cross-
over trial of 4-AP in DBN, a dosage of 5 mg four times a
day reduced postural sway particularly in older patients
[19]. Slow phase velocity (SPV) decreased from 2.42/s at
baseline to 1.38/s with 5 mg 4-AP, 60 min after drug
administration. Near visual acuity increased significantly
from 0.59 at baseline to 0.66 with 4-AP. Using age as a
covariate, increasing age correlated significantly with the
4-AP-related decrease in SPV. However, there were no
differences between 4-AP and placebo regarding patient
satisfaction and side effects [19]. This lack of subjective
improvement may be overcome by the sustained-release
form of 4-AP, which has shown its efficacy in an obser-
vational study [20]. Therefore, further trials on the sus-
tained-release formulation are needed to confirm these
results and to evaluate the long-term effects of 4-AP.
In conclusion, 4-AP in a dosage of 5 mg two to four
times per day is recommended for the treatment of DBN;
patients should have an electrocardiogram both at baseline
and about 45 min after taking 4-AP to exclude QT
interval prolongation. The sustained-release form of 4-AP,
which is approved for the treatment of gait disorders in
MS, can also be used in a dosage of 10 mg one to two
times per day.
Table 1 Current ongoing randomized clinical trials for central vestibular disorders at the German Center for Vertigo, Munich. A, B, and C are
funded by the Federal Ministry of Research
(A) Vestibular migraine Metoprolol (95 mg/d) versus placebo: PROVEMIG-trial
(B) Episodic ataxia type 2 Fampridine (20 mg/d) versus acetazolamide (750 mg/d) versus placebo: EAT-2-TREAT-trial
(C) Cerebellar ataxia Acetyl-DL-leucine (5 g/d) versus placebo: ‘‘ALCAT-trial’’
(D) Cerebellar gait ataxia Fampridine (20 mg/d) versus placebo: ‘‘FACEG-trial’’
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Fig. 1 3D eye movement raw data of DBN. Vertical eye position
data in three different vertical eye positions (±18, up ‘‘–deg’’, down
‘‘?deg’’) while fixating a continuously visible target. The recordings
were performed before and 90 min after ingestion of 10 mg 4-AP
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Chlorzoxazone (CHZ), a non-selective activator of
small-conductance, calcium-activated potassium channels
(SK channels), was evaluated as a potential new substance
for the symptomatic treatment of DBN. This pilot study
showed that CHZ 500 mg 3 times a day may improve eye
movements and visual acuity [21]. Based on these findings,
a randomized placebo-controlled trial is necessary.
Upbeat nystagmus (UBN) is another form of acquired
vertical nystagmus, which manifests with oscillopsia due to
retinal slip of the visual scene and postural instability. It
usually increases with upgaze and is analogous to DBN
associated with impaired upward pursuit [22]. It can be
caused by lesions at several separate sites of the brain stem
or the cerebellum, such as the anterior cerebellar vermis,
the pontomesencephalic junction, or the medulla. Possible
causes are ischemia, multiple sclerosis, tumor, cerebellar
degeneration, or Wernicke’s encephalopathy [7]. The
pathophysiological hypothesis describes an imbalance of
the vertical vestibulo-ocular reflex tone as suggested for
DBN. The competing hypothesis postulates a deficiency of
the neural velocity-to-position integration of eye move-
ments [23]. In an uncontrolled study, only moderate suc-
cess was shown for the GABAergic substance baclofen
(5–10 mg/3 times a day) [24]. In a single case report,
10 mg of 4-AP reduced UBN effectively and restored the
impaired upward smooth pursuit, probably by improving
the function of cerebellar pathways that mediate gaze
holding and smooth pursuit [25]. This result needs to be
corroborated in a larger cohort of UBN patients to deter-
mine the usefulness of aminopyridines in different forms of
UBN. However, in contrast to downbeat nystagmus, UBN
usually shows a spontaneous recovery, which makes
medical treatment clinically less relevant.
There are less frequent forms of central nystagmus,
which can be improved by different agents (for an over-
view see Table 2). Patients with periodic alternating nys-
tagmus (PAN) often complain oscillopsia due to a
horizontal jerk nystagmus, which changes its direction
every 60–180 s. Like many other forms of nystagmus,
PAN is often caused by cerebellar dysfunction, in partic-
ular by lesions of the nodulus or the uvula. The treatment
of choice is the GABAergic drug baclofen in a dosage of
5–10 mg three times daily, which usually abolishes nys-
tagmus in most patients [4, 5]. Patients who are refractory
to a baclofen monotherapy might respond if the glutamate
antagonist memantine is added [4]. Acquired pendular
nystagmus (APN) is another central nystagmus, charac-
terized by quasi-sinusoidal horizontal, vertical, or torsional
components [4]. Associated symptoms, in particular ocu-
lopalatal tremor, often depend on the underlying pathology
with damage to the paramedian tract projections and den-
ervation of the inferior olive. The most common causes are
multiple sclerosis, brain stem ischemia, and Whipple’s
disease [5]. We recommend gabapentin (300–600 mg three
times daily) or memantine (20–40 mg daily) as medical
treatment. Recent reviews providing detailed therapeutic
recommendations for different forms of central nystagmus
are found elsewhere [4, 5].
Vestibular migraine
Vestibular migraine is a form of migraine in which the
patient experiences recurrent attacks of vertigo or dizziness
[6]. More recently, the diagnostic criteria were defined
more precisely by the Classification Committee of
Vestibular Disorders of the Barany Society together with
the International Classification of Headache Disorders
(ICHD) [7]. The criteria are as follows: 1. at least five
episodes with vestibular symptoms of moderate or severe
intensity, lasting 5 min to 72 h; 2. current or previous
history of migraine with or without aura according to the
ICHD; 3. one or more migraine features with at least 50 %
of the vestibular episodes: 3a. headache with at least two of
the following characteristics: one-sided location, pulsating
quality, moderate or severe pain intensity, aggravation by
routine physical activity; 3b. photophobia and phonopho-
bia; 3c. visual aura; 4. not better accounted for by another
vestibular or ICHD diagnosis [7].
Several drugs are widely used for vestibular migraine
either for the attacks or as a prophylactic treatment to
reduce the frequency; however, none of them has proven
their efficacy in clinical trials and the need for state-of-the-
art randomized controlled trials was identified in a recent
Cochrane Review [6]. There is an ongoing multicenter,
double-blind, placebo-controlled trial on the prophylactic
treatment of vestibular migraine with metoprolol 95 mg
per day [University of Munich (PROVEMIG-trial, funded
by the Federal Ministry of Education and Research)].
Table 2 Treatment for different forms of central nystagmus, which
can be improved by pharmacological agents
Pharmacological treatment of central nystagmus forms
Nystagmus Medication Dosage
DBN 3,4-DAP 10 mg PO tid
4-AP 5–10 mg PO tid
UBN 4-AP 5–10 mg PO tid
PAN Baclofen 5–10 mg PO tid
APN Gabapentin 300–600 mg PO tid (up to 2400 mg/d)
Memantine 20–40 mg PO/d
DBN downbeat nystagmus, UBN upbeat nystagmus, PAN periodic
alternating nystagmus, APN acquired pendular nystagmus, 3,4-DAP
3,4-Diaminopyridine, 4-AP 4-aminopyridine, d day, tid three times
daily
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Episodic ataxia type 2
EA2 is the most frequent form of inherited syndrome with
recurrent attacks of vertigo and ataxia and is caused by
mutations of the CACNA1A gene encoding the a-subunit
of a P/Q-type calcium channel [26]. Symptoms are recur-
rent vertigo and ataxic symptoms lasting up to several
hours, which are often elicited by stress, physical activity,
or alcohol [27]. The patients often show oculomotor dis-
turbances such as DBN, saccadic smooth pursuit, or gaze-
holding deficits even outside of attacks [28], which might
allow the clinican to differentiate EA2 from vestibular
migraine with minor ocular motor deficits [29, 30]. About
two-thirds of EA2 patients respond to the carboanhydrate
inhibitor acetazolamide (250–1000 mg/d) [31], which has
been the first-line treatment for many years. However,
there are so far no randomized, placebo-controlled trials on
the efficacy of acetazolamide. Furthermore, the side effects
of acetazolamide (e.g., kidney stones, nephrocalcinosis,
paresthesia, muscle stiffening with easy fatigability,
hyperhydrosis) often limit its therapeutic use in clinical
practice.
In 2004, a case series on three patients with EA2 showed
a reduction in the number of attacks [32]. These findings
were confirmed in a randomized, placebo-controlled trial in
ten subjects with EA-2. During the study, the median
monthly attack frequency under placebo was 6.5 and
decreased to 1.65 under medication with 4-AP [33]. Fur-
thermore, the median monthly attack duration was reduced
and the quality of life as measured by the Vestibular
Disorders Activities of Daily Living Scale improved.
Prior to the results of the controlled trial, animal studies
in EA2 mutant mice showed that 4-AP raised the threshold
for the triggering of the episodic attacks [34]. Moreover,
the precision of pacemaking in Purkinje cells was restored
by prolonging and increasing the action potential after
hyperpolarization by targeting the K(v)1 family of K(?)
channels [34]. Interestingly, the therapeutic efficacy of
4-AP was comparable and not greater than that of chlor-
zoxazone, which also restores the precision of Purkinje cell
pacemaking. Because 4-AP in higher concentrations blocks
a large array of K?channels, the development of more
selective drugs for a safer treatment of cerebellar ataxia is
necessary.
More recently, a case series showed the efficacy of the
sustained-release form of 4-AP [35]. The recommended
dosage of 4-AP is 5–10 mg three times a day. There is
currently an ongoing placebo-controlled trials on 4-AP in
EA2 investigating the sustained-release form of 4-AP
versus acetazolamide versus placebo (University of
Munich, EAT2TREAT, funded by the Federal Ministry of
Education and Research).
Cerebellar ataxias
Cerebellar syndromes due to neurodegenerative and
hereditary diseases often lead to postural instability asso-
ciated with cerebellar ocular motor disorders such as DBN,
gaze-evoked nystagmus, deficient smooth pursuit, and
dysmetric saccades [9]. These ocular motor deficits are
leading symptoms that help to uncover mild forms of
cerebellar ataxia in the absence of further deficits such as
ataxia of the extremities, speech disturbances, or
unsteadiness of gait.
The treatment of cerebellar motor deficits remains dif-
ficult in both recessive and dominant cerebellar ataxias.
Clinical studies are often performed in genetically hetero-
geneous or genetically non-defined degenerative cerebellar
syndromes, while large randomized-cohort studies on
cerebellar symptoms are lacking, and so far no pharma-
cological intervention has been proven effective [36].
Recently, aminopyridines improved the motor behavior in
Fig. 2 Individual changes of cerebellar patients on a Scale for the Rating and Assessment of Ataxia (SARA) and b Quality of Life Questionnaire
Euro-Qol-5D-3L (EQ-5D-3L) on medication with acetyl-dl-leucine (5 g/day) for 9 ± 3 days [40]
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a mouse model of spinocerebellar ataxia type 1 [37]. Those
mice who were treated early in the course of the disease
demonstrated better motor performance, which might be
due to a neuroprotective effect mediated by an enhanced
electrical activity of cerebellar Purkinje cells [37]. Cur-
rently, aminopyridines and acetazolamide may be the only
effective drug for a subset of cerebellar symptoms [36]. In
a retrospective case series, patients with cerebellar gait
disorders due to different etiologies also benefitted from
4-AP [38]. The sustained-release form of 4-AP showed
modest short-term improvements in a short-term trial with
16 patients with cerebellar ataxia (SAOA, SCA1/3/6,
POLG mutation) [39]. These observations are currently
being evaluated further in two placebo-controlled trials
[University of Florida (NCT01811706), University of
Munich (FACEG)].
Finally, the modified amino-acid acetyl-DL-leucine
might be another drug to improve ataxia. Acetyl-DL-leu-
cine has been used in France for more than 50 years for the
symptomatic treatment of vertigo. In a case series, this
substance improved ataxia (Fig. 2) and dysarthrophonia in
a variety of patients suffering from cerebellar ataxia [40].
In a case series on patients with Niemann-Pick type C,
acetyl-DL-leucine significantly improved ataxic symptoms
without relevant side effects, thus showing a reasonable
risk–benefit profile [41]. Finally, a PET study in patients
with ataxia of different etiologies given AL demonstrated
an increased metabolism in the midbrain and lower brain
stem in responders [42].
In an animal model of acute unilateral labyrinthectomy,
acetyl-DL-leucine restored the membrane potential of both
depolarized and hyperpolarized vestibular neurons, presum-
ably by interacting with membrane phospholipids such as
phosphatidylinositol 4,5-bisphosphate [43, 44]. Thus, acetyl-
DL-leucine may regulate the membrane potential of cerebel-
lar Purkinje cells and therefore influence motor control and
adaptive vestibular–cerebellar mechanisms. The recent clin-
ical findings form the basis for a multi-national, placebo-
controlled trial on the effects of acetyl-DL-leucine on cere-
bellar ataxia (ALCAT, funded by the Federal Ministry of
Education and Research, first patient in: Dec 15th 2015).
Conclusion
Recently progress has been made in the pharmacotherapy
of nystagmus and cerebellar disorders. The treatment of
several central vestibular disorders (DBN, UBN), and
cerebellar disorders (EA2) with aminopyridines has proven
to be effective. Randomized controlled trials with the
sustained-release form of 4-AP in patients with cerebellar
gait disorder and EA2 are on their way.
However, we need further placebo-controlled trials for
new promising agents such as chlorzoxazone. In cerebellar
ataxia, a prospective, randomized, placebo-controlled,
multinational trial is currently being initiated to investigate
the action of acetyl-DL-leucine on cerebellar symptoms
(ALCAT, funded by the BMBF). Finally, more transla-
tional research will help us to find new therapeutic strate-
gies and increase the quality of life of our patients.
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